Emergence of and risk factors for ciprofloxacin-gentamicin-resistant Escherichia coli urinary tract infections in a region of Quebec

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 20, Issue 4, 2009, Pages

  Pépin, Jacques ^a   Plamondon, Mireille ^a   Lacroix, Caroline ^a   Alarie, Isabelle ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Canada; Ciprofloxacin; Escherichia coli; Gentamicin; Urinary tract infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

AGING; ANTIBIOTIC THERAPY; ARTICLE; ASYMPTOMATIC BACTERIURIA; BACTEREMIA; CANADA; CASE CONTROL STUDY; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTITIS; ESCHERICHIA COLI; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NURSING HOME PATIENT; PREVALENCE; PYELONEPHRITIS; RISK FACTOR; SEPTIC SHOCK; SEX DIFFERENCE; URINARY TRACT INFECTION;

EID: 73949142292     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/971624     Document Type: Article

References (34)

1. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 1999;29:745-58.
2. Miller LG, Tang A. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004;79:1048-54.
3. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: A population-based assessment. Infection 2007;35:150-3.
4. Salgado CD, Krachmer TB, Farr BM. Prevention of catheter associated urinary tract infections. In: Wenzel RP, ed. Prevention and Control of Nosocomial Infections. Philadelphia: Lippincott Williams & Wilkins, 2003:297-311.
5. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40:643-54.
6. Czaja C, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007;45:273-80.
7. Foxman B, Moran K, Brown P. Antibiotic resistance and pyelonephritis. Clin Infect Dis 2007;45:281-3.
8. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units, implications for fluoroquinolones use. JAMA 2003;289:885-8.
9. Diekema DJ, BootsMiller BJ, Vaughn TE, et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004;38:78-85.
10. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J. Antimicrobial- resistant invasive Escherichia coli, Spain. Emerg Infect Dis 2005;11:546-53.
11. Stelling JM, Travers K, Jones RN, Turner PJ, O'Brien TF, Levy SB. Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg Infect Dis 2005;11:873-82.
12. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540-5.
13. Karlowsky JA, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003;47:1672-80.
14. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother 2003;51:69-76.
15. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university in Taiwan. Int J Antimicrob Agents 2005;26:463-72.
16. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolones resistance among Enterobacteriaceae isolates from inpatients and outpatients 1999-2000; differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004;38:655-62.
17. Chaniotaki S, Giakouppi P, Tzouvelekis LS, et al. Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece. Clin Microbiol Infect 2004;10:75-8.
18. McDonald C, Chen FJ, Ho HJ, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 2001;45:3084-91.
19. Hanberger H, Garcia-Rodrigues JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999;281:67-71.
20. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quiolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999;43:2736-41.
21. Martinez-Freijo P, Fluit AD, Smitz FJ, Grek VS, Verhoef J, Jones ME. Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. J Antimicrob Chemother 1998;42:689-96.
22. Wang F, Zhu DM, Zhang YY. Surveillance of bacterial resistance among isolates in Shanghai in 1999. J Infect Chemother 2001;7:117-20.
23. Shannon K, French G. Increasing resistance to antimicrobial agents of Gram-negative organisms at a London teaching hospital 1995-2000. J Antimicrob Chemother 2004;53:818-25.
24. McIsaac WJ, Mazzulli T, Permaul J, Moineddin R, Low DE. Community-acquired antibiotic resistance in urinary isolates from adult women in Canada. Can J Infect Dis Med Microbiol 2006;17:337-40.
25. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, January 2008.
26. European Committee on Antimicrobial Susceptibility testing. Cephalosporins - EUCAST clinical MIC breakpoints. http://www.srga.org/eucastwt/ MICTAB/MICcephalosporins.html (Version current at June 29, 2009).
27. Emori TG, Cluver DH, Horan TC, et al. National nosocomial infections surveillance system (NNIS): Description of surveillance methods. Am J Infect Control 1991;19:19-35.
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies. Development and validation. J Chronic Dis 1987;40:373-83.
29. Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007;60:855-63.
30. Robicsek A, Jacoby GA, Hooper D. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006;6:629-40.
31. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006;12:83-8.
32. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000;31:S24-S28.
33. Mulvey MR, Bryce E, Boyd D, et al. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother 2004;48:1204-14.
34. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management. Clin Infect Dis 2006;43:432-8.